Biotech Values

[TechandBio]

PLX sitting on the standard of care (will become) in a current $2.1 billion Fabry ERT market - growing to nearly $3 billion by end of decade… and sport a $65 million market cap. Ridiculously undervalued is an understatement. Companies Platform is validated with FDA approved drug with Pfizer for Gaucher. 2023 Approvals in Europe & the US are expected to pass with flying colors Q1 & Q2 2023. Chiesi PLX partner on 102 Fabry has negotiated 15-35% royalties is Europe & 15-40% royalties in the USA with 1.1 Billion in milestones that kick in on Approvals. 3 Phase 3 Completed.
Happy New Year!

$PLX